Novartis AG ADR

Novartis posted a mixed third quarter for fiscal 2025, clearing the revenue bar while falling slightly short on earnings, as robust volume-driven growth across its oncology and immunology franchises ran into the weight of generic erosion and a sizable legal charge. Revenue came in at $13.91 billion, edging past the $13.85 billion consensus by 0.45% and marking a 5.6% year-over-year gain, yet core EPS of $2.25 missed the $2.31 analyst estimate by 2.63%, weighed in part by a $443 million expense tied to a French court reversal in the Lucentis/Avastin antitrust case. The headline growth story remained the company's newer blockbusters, with Kisqali surging 69% to $1.33 billion and Kesimpta climbing 46% to $1.22 billion, while Pluvicto added further momentum after new data showed the radioligand therapy reduced the risk of disease progression or death by 28% in hormone-sensitive prostate cancer, potentially doubling its eligible patient pool. Net debt climbed to $20.40 billion, reflecting aggressive M&A spending including the $12 billion deal to acquire Avidity Biosciences.